Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status

Summary

The goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and improve partial or complete response rate over each treatment. The main questions it aims to answer are: * What is the response rate of the cancer to paclitaxel after priming with toripalimab * What is the time to progression if we continue to cycle between toripalimab and paclitaxel * What is the impact on the patient's quality of life and overall survival

Timeline

Start

2026-09-30

Primary completion

2028-05-29

Completion

2029-05-29

Drugs

Indications